BioSpace News Archive

Drug Development

CymaBay Therapeutics Announces Publication of Results From a 52-Week, Open-Label, Phase 2 Study of Seladelpar in Patients With Primary Biliary Cholangitis

CymaBay Therapeutics, Inc. today announced that results from the Phase 2, 52-week study of seladelpar in patients with primary biliary cholangitis (PBC) have been published in the Journal of Hepatology.

April 4, 2022
·
7 min read
Business

Vipergen Establishes DNA Encoded Library (DEL)-Based Drug Discovery Partnership with Theseus Pharmaceuticals Focused on Targeted Cancer Therapies

Vipergen, announced today the signing of a drug discovery agreement with Theseus Pharmaceuticals, a clinical-stage biopharmaceutical company focused on improving the lives of cancer patients through the discovery, development, and commercialization of transformative targeted therapies.

April 4, 2022
·
1 min read
Drug Development

BeyoND Phase 2b Data Indicates ND0612 Has a Positive Long-Term Safety Profile for People with Parkinson’s Disease

NeuroDerm Ltd., a wholly owned subsidiary of Mitsubishi Tanabe Pharma Corporation, announced positive, long-term safety and tolerability data for ND0612 at the American Academy of Neurology Annual Meeting (in Seattle, April 2-7, and virtually, April 24-27).

April 4, 2022
·
6 min read
Pharm Country

Harmony Biosciences To Participate In 21st Annual Needham Virtual Healthcare Conference

Harmony Biosciences Holdings, Inc. announced that Harmony’s President and CEO, John C. Jacobs, will present a company update and host investor meetings at the upcoming 21st Annual Needham Virtual Healthcare Conference.

April 4, 2022
·
1 min read
Drug Development

Blade Therapeutics Announces Feedback from FDA on End-of-Phase 1 Data Package

Blade Therapeutics, Inc. today announced receipt of feedback from the FDA regarding the company’s end-of-phase 1 data package for cudetaxestat, an investigational non-competitive autotaxin inhibitor in clinical development for treatment of IPF and other fibrotic diseases.

April 4, 2022
·
14 min read
Deals

Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Astria Therapeutics, Inc. granted equity awards on April 1, 2022 under Astria’s 2022 Inducement Stock Incentive Plan.

April 4, 2022
·
1 min read
Genetown

Genocea Biosciences to Host Investor Webinar

Genocea Biosciences, Inc. today announced details for a planned investor webinar to coincide with the American Association for Cancer Research (AACR) Annual Meeting 2022, taking place April 8-13.

April 4, 2022
·
2 min read
Genetown

Checkpoint Therapeutics to Present at the Virtual Fortress Biotech R&D Summit Hosted by B. Riley Securities

Checkpoint Therapeutics, Inc. today announced that members of Checkpoint’s management team will participate in the two-day Fortress Biotech (“Fortress”) Virtual R&D Summit taking place on Tuesday, April 5, 2022 and Wednesday, April 6, 2022.

April 4, 2022
·
5 min read
Biotech Beach

Resolve Biosciences to Showcase Agrigenomic Applications for Molecular Cartography™ Platform at Advances in Genome Biology and Technology Agriculture Meeting

Resolve Biosciences to Showcase Agrigenomic Applications for Molecular Cartography ™ Platform at Advances in Genome Biology and Technology Agriculture Meeting.

April 4, 2022
·
4 min read
Biotech Bay

V Foundation Raises $2.4 Million for Cancer Research at the Inaugural Sonoma Epicurean

The V Foundation for Cancer Research raised over $2.4 million at the inaugural Sonoma Epicurean weekend, held March 31 - April 3 in Sonoma County’s renowned wine country.

April 4, 2022
·
2 min read